Company Cash on Hand: altoneuroscience.com (ANRO)

Graphic logo of Alto Neuroscience, Inc. (ANRO)

The cash on hand metric on the GURU.Markets chart demonstrates liquidity, where the current level is 0.32. Alto Neuroscience, Inc. (ANRO) is implementing AI and biomarkers for precision therapy for schizophrenia and depression. The company is developing partnerships with medical centers to create personalized medicines. However, the lack of profitable products makes the business dependent on external venture investments in the absence of its own cash flow.

Company Cash and Cash Equivalents: Alto Neuroscience Inc (ANRO) for 02/21/2024 - 11/21/2026

Analytical breakdowns for Alto Neuroscience, Inc.

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Fundamental valuation:ANRO Alto Neuroscience Inc
Product sample of Alto Neuroscience

For Alto Neuroscience, Inc. (ANRO), which develops precision psychiatry and biomarker-driven drugs, liquidity availability is a critical survival factor during the active clinical development phase. The cash-on-hand trend reflects the daily cash balance, allowing investors to assess solvency and the business's autonomy horizon between quarterly reports, balancing financial stability with capital efficiency.